Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01113632 | Completed Phase 2 Results

• 1 other identifier: SCRI CLL 11
• Study Type: interventional
• Target: 77
• Locations: 1 country
• Sites: 13

Brief Summary

The risk of immunosuppression deters many patients from receiving fludarabine, while combination chemotherapy regimens are poorly tolerated by elderly or infirm chronic lymphocytic leukemia (CLL) patients. Previous studies by our group and others have shown that rituximab is safe and well tolerated when used as a single agent in patients with CLL. In addition, maintenance therapy with rituximab was well tolerated by CLL patients, with probable prolongation of progression-free survival (Hainsworth et al. 2003). Based on pre clinical and clinical studies indicating possible increased efficacy of ofatumumab in patients with CLL, we wish to develop an antibody-only regimen for older patients and patients who refuse fludarabine-based regimens.

Conditions

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Keywords

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Ofatumumab

Outcome Measures

Primary Outcomes (1)

• Overall Response Rate (ORR)

  The Number of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

  18 months

Secondary Outcomes (4)

• Progression-free Survival (PFS)

  18 months

• Number of Complete Responses

  18 Months

• Number of Partial Responses

  18 Months

• Safety of the Treatment Regimen

  18 Months

Study Arms (2)

Ofatumumab 1000mg

EXPERIMENTAL

Ofatumumab 300mg IV Day 1 followed by ofatumumab 1000mg weekly for a total of 8 weeks

Drug: Ofatumumab

Ofatumumab 2000mg

EXPERIMENTAL

Ofatumumab 300mg IV Day 1 followed by ofatumumab 2000mg weekly for a total of 8 weeks

Drug: Ofatumumab

Interventions

Ofatumumab DRUG

IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.

Ofatumumab 1000mg; Ofatumumab 2000mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• CD20+ B-cell chronic lymphocytic leukemia (B-CLL) or small lymphocytic lymphoma according to NCI criteria (see Appendix B).
• Previously untreated CLL or small lymphocytic lymphoma (SLL).
• Patients must require treatment according to NCI-Working Group guidelines (see Appendix C).
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤2 (see Appendix A).
• Laboratory values as follows ≤7 days of initiation of treatment:
• Creatinine \<3.0 mg/dL
• Aspartate amino transferase (AST) or alanine amino transferase (ALT) and alkaline phosphatase (ALP) must be \<3 x upper limit of normal (ULN)
• Total bilirubin \<1.5 x the institutional ULN
• Patients must be hepatitis B sAg negative. Note: Patients who are HepB sAg negative but are HepB cAb positive (regardless of HepB sAb status) will NOT be allowed.
• Women of childbearing potential must have a negative serum pregnancy test performed ≤7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.
• Patients ≤ 65 years of age, or patients 18-64 years of age who have declined fludarabine-based regimens, are eligible.
• Patient must be accessible for treatment and follow-up.
• Patients must be able to understand the nature of this study, give written informed consent prior to study entry, and comply with study requirements.

You may not qualify if:

• Previous therapy for CLL/SLL. (Patients who have received steroids or IVIG for autoimmune complications of CLL are eligible).
• Current active hepatic or biliary disease (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease, per assessment by the treating physician).
• Active bacterial or viral infection, or infection requiring intravenous antibiotic treatment at the time of accrual.
• Central nervous system lymphoma/CLL.
• Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (i.e., Richters transformation).
• History of other malignancy within 2 years of study entry which could affect compliance with the protocol or interpretation of results. Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix, low grade, early-stage, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ (DCIS) of the breast treated with curative intent, are generally eligible. These cases should be discussed with the study chair or study co-chair prior to enrollment.
• Patients who are HepB sAg positive and/or HepB cAb positive.
• Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
• Any condition that would prevent patient comprehension of the nature of, and risk associated with, the study.
• A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
• A major surgical procedure, open biopsy, or significant traumatic injury ≤28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study.
• Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to visit 1, whichever is longer. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.

Sponsors & Collaborators

• SCRI Development Innovations, LLC: lead
• GlaxoSmithKline: collaborator

Study Sites (13)

Los Robles

Thousand Oaks, California, 91360, United States

Location

Florida Cancer Specialists

Fort Myers, Florida, 34236, United States

Location

Woodlands Medical Specialists

Pensacola, Florida, 32503, United States

Location

Northeast Georgia Medical Center

Gainesville, Georgia, 30501, United States

Location

Providence Medical Group

Terre Haute, Indiana, 47802, United States

Location

St. Louis Cancer Care

Chesterfield, Missouri, 63017, United States

Location

Portsmouth Regional Hospital

Portsmouth, New Hampshire, 03801, United States

Location

Hematology-Oncology Associates of Northern NJ

Morristown, New Jersey, 07960, United States

Location

Oncology Hematology Care

Cincinnati, Ohio, 45242, United States

Location

The Ohio State University

Columbus, Ohio, 43210, United States

Location

South Carolina Oncology Associates

Columbia, South Carolina, 29210, United States

Location

Chattanooga Oncology Hematology Associates

Chattanooga, Tennessee, 37404, United States

Location

Tennessee Oncology

Nashville, Tennessee, 37203, United States

Location

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

ofatumumab

Condition Hierarchy (Ancestors)

Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: John D Hainsworth, MD
• Organization: Sarah Cannon Research Institute

asksarah@scresearch.net

1-877-691-7274

Study Officials

• Ian Flinn, M.D.

  SCRI Development Innovations, LLC

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2010
• First Posted: April 30, 2010
• Study Start: July 1, 2010
• Primary Completion: March 1, 2015
• Study Completion: August 1, 2016
• Last Updated: September 20, 2016
• Results First Posted: June 4, 2015

Record last verified: 2016-08

Locations

US (13)